Focused-ultrasound developer InSightec will debut two new additions to its ExAblate line of MR-guided focused ultrasound systems at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010 meeting in Valencia, Spain.
ExAblate One will provide treatment of uterine fibroids and adenomyosis, while ExAblate OR is a noninvasive, image-guided, and controlled acoustic operating room, according to the Tirat Carmel, Israel-based vendor.
ExAblate OR provides commercially approved and research treatment options for clinical indications such as uterine fibroids and adenomyosis, breast cancer, prostate cancer, and pain palliation of bone metastases, InSightec said. Both ExAblate One and ExAblate OR are compatible with the Signa and Discovery MRI product lines from GE Healthcare of Chalfont St. Giles, U.K.
Related Reading
InSightec treats prostate cancer patients, August 31, 2010
InSightec gets Japanese clearance, January 13, 2010
Study: InSightec's ExAblate helps with pain, July 14, 2009
InSightec notches $15 million investment, March 19, 2009
InSightec raises $30 million, November 30, 2007
Copyright © 2010 AuntMinnie.com
